takeaway
put anoth big organ growth beat vs drove
decent ep upsid help continu robust demand across
segment end-mkt guidanc move fulli captur
upsid leav room posit revis see littl critic
latest print outsid weak also wonder much better
get wait better entri point
everyth great core revenu growth ex-feic wallop
consensu top even optimist whisper broad strength across
segment end-market geograph apac stand-out led china
even acceler bit segment lss lp sd grew
ai ex-feic grew third straight period
guidanc hike still leav room bump ep guidanc
mid-pt account upsid fx integenx deal
still see room upsid core growth fx note growth
outlook vs prior captur half upsid
mean view increment conserv current
rate figur fx could add rev ep top bake
guidanc bottom line end market condit stay firm like much
upsid left come period view
biopharma strength persist gain share mass spec biopharma
show sign slow momentum mass spec lc remain robust
believ gain share hesit extrapol much one
period think much weaker mass spec lend credibl view
perhap real blotch otherwis good
season weaker cash flow period unusu slow start
also held outlook despit rais ep
stock good fundament room upsid admit
may con rel safe time expect high
stock outperform ytd rel valuat high stock alreadi seem
discount upsid
pt repres horizon dcf impli ev ufcf
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
million except per share data
page
pleas see import disclosur inform page report
vs growthv expectationspriorforecastreportedactualpercentactualpercentepsnet product expens share share analysisgross research sg ebitda oper incom incom net
million except per share data
page
pleas see import disclosur inform page report
histor earn per flow cash cash flow cash flow per cash net interest free cash sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
